Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H12O4 |
Molecular Weight | 244.2427 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC(O)=C(\C=C\C2=CC(O)=CC(O)=C2)C=C1
InChI
InChIKey=PDHAOJSHSJQANO-OWOJBTEDSA-N
InChI=1S/C14H12O4/c15-11-4-3-10(14(18)8-11)2-1-9-5-12(16)7-13(17)6-9/h1-8,15-18H/b2-1+
Molecular Formula | C14H12O4 |
Molecular Weight | 244.2427 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Hydroxyresveratrol (Oxyresveratrol) is a major active compound in the heartwood of Artocarpus lacucha. It was first isolated from the heartwood of Artocarpus lakoocha, and has also been found in various plants, including Smilax China, Morus alba, Varatrum nigrum, Scirpus maritinus, and Maclura pomifera. Oxyresveratrol, an aglycone of mulberroside A, has been produced by microbial biotransformation or enzymatic hydrolysis of a glycosylated stilbene mulberroside A, which is one of the major compounds of the roots of M. alba.
Oxyresveratrol plays an important role in anti-tyrosinase, antioxidant, anti-inflammatory, antiviral and neuroprotective properties. There are many A. lacucha commercial products available on the market for skin whitening and anti-aging effects. OxyResvenox™ is the registered trademark of Oxyresveratrol from Sabinsa. Oxyresveratrol is an analog of Resveratrol and is of synthetic origin. The hydroxystilbene compounds including oxyresveratrol and resveratrol showed the potent inhibitory effect on tyrosinase activity. Oxyresveratrol is also naturally present in Morus alba L., Morus bombycis. Oxyresveratrol exhibits a potent inhibitory effect on dopa oxidase activity of tyrosinase
which catalyzes rate-limiting steps of melanin biosynthesis. Oxyresveratrol showed superoxide scavenging effects with the IC50 values 3.81 ± 0.5 uM,
Oxyresveratrol exhibited a DPPH free radical scavenging effect (IC50 = 23.4 ± 1.5 uM).
Oxyresveratrol also showed hepatoprotective effects with EC50 values 32.3 ± 2.62 uM, on
tacrine-induced cytotoxicity in human liver-derived Hep G2 cells. Oxyresveratrol significantly inhibited LPS-evoked nuclear translocation of NF-kappaB and
cyclooxygenase-2 (COX-2) activity in RAW 264.7 cells.
The results suggest that the anti-inflammatory properties of oxyresveratrol might be
correlated with inhibition of the iNOS expression through down-regulation of NF-kappaB
binding activity and significant inhibition of COX-2 activity. Oxyresveratrol revealed a dose-dependent neuroprotective effect in an in vivo stroke model.
This may prove to be beneficial for a therapeutic strategy to limit brain injury in acute brain ischemia.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL612649 Sources: https://www.ncbi.nlm.nih.gov/pubmed/29024160 |
|||
Target ID: WP408 |
23.4 µM [IC50] | ||
Target ID: CHEMBL1973 |
12.7 µM [IC50] | ||
Target ID: CHEMBL2649 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11858749 |
1.4 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | OxyResvenox Approved UseSkin lightening support |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15261105
Curator's Comment: Humans: topical - Recommended usage level in cosmetic and
personal care applications is 0.05 – 0.2% w/w
of the composition. http://www.esbalabs.com/assets/images/Bump-and-Blemish/Oxyresvenox-skin-brightener.pdf
Rats: Oxyresveratrol (10 or 20 mg/kg) significantly reduced the brain infarct volume by approximately 54% and 63%, respectively, when compared to vehicle-treated MCAO rats. Oxyresveratrol (2, 10, 20 and 30 mg/kg body weight in a total volume of 1 ml in 30% ethanol) or equal volumes
of the vehicle were administered intraperitoneally (i.p.) in
animals twice: at the time of occlusion and at the time
of reperfusion.
Route of Administration:
Intraperitoneal
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 20:02:11 GMT 2023
by
admin
on
Sat Dec 16 20:02:11 GMT 2023
|
Record UNII |
6V071CP5CR
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6V071CP5CR
Created by
admin on Sat Dec 16 20:02:11 GMT 2023 , Edited by admin on Sat Dec 16 20:02:11 GMT 2023
|
PRIMARY | |||
|
DTXSID801030442
Created by
admin on Sat Dec 16 20:02:11 GMT 2023 , Edited by admin on Sat Dec 16 20:02:11 GMT 2023
|
PRIMARY | |||
|
5281717
Created by
admin on Sat Dec 16 20:02:11 GMT 2023 , Edited by admin on Sat Dec 16 20:02:11 GMT 2023
|
PRIMARY | |||
|
C515052
Created by
admin on Sat Dec 16 20:02:11 GMT 2023 , Edited by admin on Sat Dec 16 20:02:11 GMT 2023
|
PRIMARY | |||
|
29700-22-9
Created by
admin on Sat Dec 16 20:02:11 GMT 2023 , Edited by admin on Sat Dec 16 20:02:11 GMT 2023
|
PRIMARY | |||
|
6V071CP5CR
Created by
admin on Sat Dec 16 20:02:11 GMT 2023 , Edited by admin on Sat Dec 16 20:02:11 GMT 2023
|
PRIMARY | |||
|
Oxyresveratrol
Created by
admin on Sat Dec 16 20:02:11 GMT 2023 , Edited by admin on Sat Dec 16 20:02:11 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT |
Activity against BACE-1 with Ki value of 5.4 x 10-6M and IC50 of 7.6 x 10-5M.
|